Children's Hospital of Los Angeles Los Angeles, CA, United States
Michal Cidon1, Beverley Newman2, Terry Robinson3, Paul Iskander4, Paul Thacker5, Evan Zucker2, Tzielan Lee6 and Rex Moats3, 1Children's Hospital Los Angeles, Los Angeles, CA, 2Stanford Children's Health, Stanford, CA, 3Children's Hospital of Los Angeles, Los Angeles, CA, 4University of California Los Angeles, Los Angeles, CA, 5Mayo Clinic, Rochester, MN, 6Stanford University School of Medicine, Palo Alto, CA
Background/Purpose: We presented preliminary data in 2021 to support the feasibility of using a semi-quantitative chest CT scoring system (Pediatric Rheumatologic Diffuse Lung Disease Score [PRDLDS]) to evaluate the prevalence of diffuse lung disease (DLD) assessed by CT in pediatric rheumatologic patients. Our initial scoring data, after preliminary radiologic training, demonstrated mild parenchymal disease and no emphysema, but high inter-rater variability for parenchymal scoring in such patients. In addition, we noted inaccurate scoring based on the pulmonary hypertension (PHT) domain of the PRDLDS. The purpose of this follow-up study was to determine the effectiveness to improve the diagnostic performance of pediatric radiology scorers in evaluating lung disease in PR patients by providing more extensive training with a modified PRDLDS scoring system without pulmonary hypertension and emphysema (MPRDLDS, Table 1).
Methods: Initially three radiologists with varying DLD scoring experience independently read 1-2 mm inspiratory chest CT scans (96 non-contrast/24 Contrast) in 120 pediatric subjects (DG: N=42 PR patients with DLD; DCG: N=34 PR patients without DLD; and NCG: N=44 pediatric normal control subjects with chest CT scans) from 3 medical centers (Children's Hospital of LA, Stanford Children's Health, Mayo Clinic). After more extensive training with these radiologists using the MPRDLDS, they read 60 cases of the original 120 cases (DG: N=30; DCG: N=20; and NCG: N=10). We compared the scores before (N=120 cases) and after (N=60 cases) this training. Demographic and disease representation of the cases was similar between the groups (Table 2).
Results: With further training, there was overall more pronounced disease detected by all readers for the DG noted from initial scoring (N=120) to the follow-up scoring (N=60); there was also no significant difference between readers for aggregate parenchymal scores (MTPS) and total MPRDLDS (Table 3). In addition, control groups (DCG, DCG) previously evaluated to have minimal to no DLD were now evaluated to have essentially no DLD.
Conclusion: Semi-quantitative scoring using the MPRDLDS with more extensive training is a feasible tool to detect the extent of DLD in PR patients. Our data revealed that our PR patients have mild DLD which is primarily contributed by parenchymal disease. Due to the mild nature of this pulmonary disease, more extensive training of the readers with the MPRDLDS scoring system is crucial. Table 1. Modified Pediatric Rheumatologic Diffuse Lung Disease Score (MPRDLDS)
Table 2. Patient Demographics and Disease
Table 3. Scoring Domains and Total Score for (MPRDLDS) Before (Nf60) and After ( Nf120) Training Disclosures: M. Cidon, None; B. Newman, None; T. Robinson, None; P. Iskander, None; P. Thacker, None; E. Zucker, None; T. Lee, None; R. Moats, None.